BFA
AIM

BlackRock Fund Advisors’s AIM ImmunoTech AIM Stock Holding History

BlackRock Fund Advisors’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$5K Buy
2
+1
+100% +$4.03K ﹤0.01% 4077
2016
Q3 		$7K Hold
1
– – ﹤0.01% 4025
2016
Q2 		$7K Hold
1
– – ﹤0.01% 4055
2016
Q1 		$7K Hold
1
– – ﹤0.01% 4051
2015
Q4 		$3K Buy
+1
New +$6.8K ﹤0.01% 4282

Other funds holding AIM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

BlackRock Fund Advisors's AIM Position: Q4 2016 in Review

BlackRock Fund Advisors increased its AIM ImmunoTech (AIM) stake by 100% in Q4 2016, buying an estimated $4.03K and bringing the position to 2 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4077.

BlackRock Fund Advisors first reported a position in AIM in Q4 2015 and has held it in 5 quarters since. The position peaked at $7K in Q3 2016. 14 funds tracked by Wall St. Rank hold AIM as of Q4 2016.

  • BlackRock Fund Advisors held 2 shares of AIM ImmunoTech worth $5K as of Q4 2016.
  • BlackRock Fund Advisors bought 1 AIM ImmunoTech share in Q4 2016, an estimated $4.03K.
  • AIM ImmunoTech made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4077 holding.
  • BlackRock Fund Advisors first reported a position in AIM ImmunoTech in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Fund Advisors's AIM ImmunoTech position peaked at $7K in Q3 2016.
  • 14 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.